The Common p.R114W HNF4A Mutation Causes a Distinct Clinical Subtype of Monogenic Diabetes.

The Common p.R114W HNF4A Mutation Causes a Distinct Clinical Subtype of Monogenic Diabetes.
复制标题

DOI:
10.2337/db16-0628
复制
发表时间:
2016-10
期刊:
影响因子:
7.7
通讯作者:
Weedon MN
Weedon MN
中科院分区:
医学1区
文献类型:
--
作者:
Laver TW;Colclough K;Shepherd M;Patel K;Houghton JA;Dusatkova P;Pruhova S;Morris AD;Palmer CN;McCarthy MI;Ellard S;Hattersley AT;Weedon MN

文献摘要

参考文献

被引文献

相似文献

HNF4A 突变导致出生体重增加、短暂性新生儿低血糖和青少年成年期发病糖尿病 (MODY)。最常报道的 HNF4A 突变是 p.R114W(以前是 p.R127W),但功能研究显示结果不一致,一些谱系中缺乏共分离,并且公共变异数据库中出现频率出乎意料地高。我们确认 p.R114W 是一种致病性突变,与对照组相比,MODY 队列中糖尿病的优势比为 30.4(95% CI:9.79 – 125,P=2x10-21)。 p.R114W杂合子的出生体重没有其他HNF4A突变患者的增加(3476g vs. 4147g,P=0.0004),并且对磺脲类治疗有反应的患者较少(48% vs. 73%,P=0.038)。 p.R114W 外显率降低;只有 54% 的杂合子在 30 岁时患上糖尿病,而其他 HNF4A 突变的杂合子则为 71%。我们将 p.R114W 重新定义为一种致病性突变,导致 HNF4A MODY 的独特临床亚型,外显率降低,对磺脲类治疗的敏感性降低,并且对出生体重没有影响。这对糖尿病治疗、妊娠管理和高危亲属的预测检测具有重要意义。大规模序列数据的可用性不断增加可能会揭示罕见、低外显率 MODY 突变的类似例子。
HNF4A mutations cause increased birth weight, transient neonatal hypoglycaemia and maturity onset diabetes of the young (MODY). The most frequently reported HNF4A mutation is p.R114W (previously p.R127W) but functional studies have shown inconsistent results, there is lack of co-segregation in some pedigrees and an unexpectedly high frequency in public variant databases. We confirm that p.R114W is a pathogenic mutation with an odds ratio of 30.4 (95% CI: 9.79 – 125, P=2x10-21) for diabetes in our MODY cohort compared to controls. p.R114W heterozygotes do not have the increased birth weight of patients with other HNF4A mutations (3476g vs. 4147g, P=0.0004) and fewer patients responded to sulfonylurea treatment (48% vs. 73%, P=0.038). p.R114W has reduced penetrance; only 54% of heterozygotes developed diabetes by age 30 compared to 71% for other HNF4A mutations. We re-define p.R114W as a pathogenic mutation causing a distinct clinical subtype of HNF4A MODY with reduced penetrance, reduced sensitivity to sulfonylurea treatment and no effect on birth weight. This has implications for diabetes treatment, management of pregnancy and predictive testing of at-risk relatives. The increasing availability of large-scale sequence data is likely to reveal similar examples of rare, low-penetrance MODY mutations.
DOI: 10.2337/db07-1633
发表时间: 2008-07-01
期刊: DIABETES
影响因子: 7.7
作者:
Harries, Lorna W.;Sloman, Melissa J.;Ellard, Sian
通讯作者: Ellard, Sian
DOI: 10.1038/384458a0
发表时间: 1996-12-05
期刊: NATURE
影响因子: 64.8
作者:
Yamagata, K;Furuta, H;Bell, GI
通讯作者: Bell, GI
DOI: 10.1007/s00125-010-1799-4
发表时间: 2010-12-01
期刊: DIABETOLOGIA
影响因子: 8.2
作者:
Shields, B. M.;Hicks, S.;Ellard, S.
通讯作者: Ellard, S.
DOI: 10.2337/diabetes.48.12.2475
发表时间: 1999-12-01
期刊: DIABETES
影响因子: 7.7
作者:
Frayling, TM;Walker, M;Hattersley, AT
通讯作者: Hattersley, AT
DOI: 10.1210/jc.84.3.1077
发表时间: 1999-03-01
影响因子: 5.8
作者:
Hegele, RA;Cao, HI;Zinman, B
通讯作者: Zinman, B